Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07108803
Enrolling by invitation Observational

European Research Group on Outcomes of Surgical Treatment of Infective Endocarditis

NCT07108803 · tracked via the Priya Life Science Italy tracker
Sponsor
Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI)
Phase
Observational
Started
2025-06-01
Last updated
2025-08-07

Condition(s) studied

Infective Endocarditis (IE)

Study summary

The European Research Group on Outcomes of Surgical Treatment of Infective Endocarditis (ERGOSTE) is a nascent large surgical registry that would encompass most relevant aspects of IE in Europe in the contemporary era.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients undergoing cardiac surgery due to infective endocarditis Exclusion Criteria: * Patients under 18 years

Primary outcome measure(s)

  • Early post-operative mortality — Mortality at 1 year after surgery

Trial sites (1)

FacilityCityRegionStatus
Cardiac Surgery Unit - ASUGI Trieste TRIESTE

Other trials for the same condition

Electronic Archive of Patients With Congenital Heart Disease and Diagnosis of Infective Endocarditis Active, not recruiting
Long Term Management and Outcomes of Surgical and Non Surgical Infective Endocarditis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07108803 on ClinicalTrials.gov ↗ ← All trials in Italy